ASB9

Across TCGA pan-cancer cohorts, ASB9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASB9 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ASB9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ASB9 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where ASB9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.971	0.482	.001	50	view →
HNSC	OS	Quartile	II,III,IV	0.877	0.590	.008	5	view →
LSCC	DFS	Quartile	All	0.528	0.859	.004	5	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.538	.043	4	view →
GBM	DFS	Median	All	0.556	0.806	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASB9–PDAC (DFS)

Open the PDAC breakdown →